Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction

NCT00365157 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

132

Enrollment

NIH

Sponsor class

Conditions

Advanced Urothelial Carcinoma
Locally Advanced Urothelial Carcinoma
Metastatic Urothelial Carcinoma
Recurrent Urothelial Carcinoma
Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
Stage IV Bladder Urothelial Carcinoma AJCC v7
Unresectable Urothelial Carcinoma

Interventions

DRUG: Eribulin Mesylate
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study

Sponsor

National Cancer Institute (NCI)